This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL
British Journal of Cancer Open Access 03 December 2019
-
Unique amplification of BCR-ABL1 gene fusion in a case of T-cell acute lymphoblastic leukemia
Molecular Cytogenetics Open Access 26 October 2017
-
In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL
Blood Cancer Journal Open Access 08 September 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Barber KE, Martineau M, Harewood L, Stewart M, Cameron E, Strefford JC et al. Amplification of the ABL gene in T-cell acute lymphoblastic leukemia. Leukemia 2004; 18: 1153–1156.
Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004; 36: 1084–1089.
Burmeister T, Gökbuget N, Reinhardt R, Rieder H, Hoelzer D, Schwartz S . NUP214-ABL1 in adult T-ALL: the GMALL study group experience. Blood 2006; 108: 3556–3559.
Stergianou K, Fox C, Russell NH . Fusion of NUP214 to ABL1 on amplified episomes in T-ALL—implications for treatment. Leukemia 2005; 19: 1680–1681.
De Keersmaecker K, Versele M, Cools J, Superti-Furga G, Hantschel O . Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. Leukemia 2008, e-pub ahead of print.
De Keersmaecker K, Porcu M, Gielen O, Cools J . LCK is a critical signaling effector in NUP214-ABL1 positive T-ALL. Haematologica 2008; 93 (s1) (abstract (0476)).
Quintas-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools J et al. Activity of tyrosine kinase inhibitors against NUP214-ABL1-positive T cell malignancies. Leukemia 2008; 22: 1117–1124.
Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK et al. In adults with standard-risk acute lymphoblastic leukemia the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827–1833.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Deenik, W., Beverloo, H., van der Poel-van de Luytgaarde, S. et al. Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia 23, 627–629 (2009). https://doi.org/10.1038/leu.2008.318
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.318
This article is cited by
-
Novel Biomarkers and Molecular Targets in ALL
Current Hematologic Malignancy Reports (2024)
-
Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma
Current Hematologic Malignancy Reports (2023)
-
Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma
Annals of Hematology (2023)
-
The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL
British Journal of Cancer (2020)
-
Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia
Leukemia (2019)